MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/cvr/cvaf152

Медицинская библиотека · Cardiovascular research · 2025

In vitro and in vivo disease models of cardiac amyloidosis: progress, pitfalls, and potential.

Qin Jiabin, Qiu Zeping, Fan Yingze, Xiong Qipeng, Lei Zhiyong, Wei Jin, van der Harst Pim, Minnema Monique C, Sluijter Joost P G, van Mil Alain, Oerlemans Marish I F J

СтатьяОбзорПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Amyloid light chain (AL) and transthyretin amyloidosis (ATTR)-induced cardiomyopathy are life-threatening protein misfolding disorders characterized by amyloid fibril deposition in the heart, which significantly impairs cardiac function. The lack of representative disease models has impeded progress in understanding the underlying mechanisms and hindered the discovery and development of specific biomarkers and effective therapies. To address this, researchers have developed various cell and animal models to recapitulate these diseases. In AL amyloidosis, cell and mouse models have highlighted the toxic effects of both soluble light chains (LCs) and LC-derived amyloid fibrils, such as lysosomal dysfunction, endoplasmic reticulum stress, and oxidative stress. Transgenic mouse models, particularly those without the mouse heavy chain and with amyloid seeds addition, have successfully replicated systemic AL amyloidosis, with clear effects on the heart. For ATTR amyloidosis, acid-induced transthyretin (TTR) fibrils induce cellular dysfunction, such as increased intracellular reactive oxygen species (ROS) level, disorganized sarcomere, and prolonged calcium handling in 2D cell models. Transgenic mouse models expressing human WT or variant TTR have offered insights into the development of amyloid cardiomyopathy, but challenges persist in fully replicating the human phenotype. This review offers a comprehensive overview of the significant advancements, challenges, and future perspectives in the development of various cell and animal models for studying AL and ATTR amyloidosis-induced cardiomyopathy, thereby providing valuable insights into disease pathophysiology, early accurate biomarkers identification, and development of novel therapies.

Для цитирования: Qin Jiabin, Qiu Zeping, Fan Yingze, Xiong Qipeng, Lei Zhiyong, Wei Jin, van der Harst Pim, Minnema Monique C, Sluijter Joost P G, van Mil Alain, Oerlemans Marish I F J. In vitro and in vivo disease models of cardiac amyloidosis: progress, pitfalls, and potential.. Cardiovascular research. 2025. DOI: 10.1093/cvr/cvaf152.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.